Main content

    HealthWise KnowledgeBase

    Hormone Therapy for Prostate Cancer (Androgen Deprivation Therapy, or ADT)

    Hormone Therapy for Prostate Cancer (Androgen Deprivation Therapy, or ADT)



    References

    Citations

    1. Saylor PJ, Smith MR (2010). Adverse effects of androgen deprivation therapy: Defining the problem and promoting health among men with prostate cancer. Journal of the National Comprehensive Cancer Network, 8(2): 211–223.

    2. Lu-Yao GL, et al. (2008). Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA, 300(2): 173–181.

    3. Nelson JB (2012). Hormone therapy for prostate cancer. In AJ Wein et al., eds., Campbell-Walsh Urology, 10th ed., vol. 3, pp. 2934–2953. Philadelphia: Saunders.

    4. Tsai HK, et al. (2007). Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Journal of the National Cancer Institute, 99(20): 1516–1524.




    By: Reference Healthwise Staff Last Revised: Reference September 12, 2012
    Medical Review: Reference E. Gregory Thompson, MD - Internal Medicine
    Reference Christopher G. Wood, MD, FACS - Urology, Oncology


    This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Reference Terms of Use. Reference How this information was developed to help you make better health decisions.


    Topic Contents